Free shipping on all orders over $ 500
About 30 results found for searched term "3-TYP" (0.007 seconds)
| Cat.No. | Name | Information |
|---|---|---|
| M1794 | SB431542 | SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM). |
| M1865 | Bevirimat | Bevirimat (BVM), also known as PA-457 or MPC-4326, is a novel Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor. |
| M1873 | LDN-193189 | LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. |
| M2000 | GW788388 | GW788388 is a potent selective inhibitor of TGF-beta type I receptor and ALK5 with IC50 values of 0.093 and 0.018 μM. |
| M2016 | LY364947 | LY364947 is a selective small molecule inhibitor of the TGFβ type I receptor kinase with IC50 of 59 nM. |
| M2106 | Azilsartan | Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM. |
| M2108 | SB-525334 | SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 of 14.3 nM. |
| M2139 | Sulfatinib | Sulfatinib is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1). |
| M2522 | Ciproxifan | Ciproxifan is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes. |
| M2797 | KRP-203 hydrochloride | Mocravimod (KRP-203) hydrochloride is a potent and orally active S1PR1 (sphingosine 1-phosphate receptor type 1) agonist. |
| M2805 | LDN-193189 Tetrahydrochloride | LDN193189 Tetrahydrochloride is the hydrochloride salt of LDN193189, which is a selective BMP signaling inhibitor, and inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, 200-fold selectivity for BMP versus TGF-β. |
| M2891 | NSC 319726 | NSC 319726 is a p53(R175) mutant activator that inhibits the growth of p53(R175) mutant cells and acts on p53(R175) mutant cells with IC50 of 8 nM, which has no inhibition on p53 wild-type cells. NSC 319726 is a potent copper ion-carrier that can be used in cuproptosis studies. |
| M3058 | Terfenadine | Terfenadine is an antihistamine compound that is normally fully metabolized in the liver by the cytochrome P450 CYP3A4 subtype enzyme into the active form fexofenadine. |
| M3125 | VU 0364770 | VU 0364770 is a positive allosteric modulator(PAM) of mGlu4 with EC50 of 1.1 μM, exhibits insignificant activity at 68 other receptors, including other mGlu subtypes. |
| M3126 | VU 0357121 | VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes. |
| M3229 | PR-104A | PR-104A is a corresponding alcohol that is systemically converted from PR-104 and a hypoxia-targeted anticancer agent with IC50 of 153 and 60 μM for wild-type CHO AA8 under aerobic and anoxic conditions. |
| M3275 | Irbesartan | Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM. |
| M3278 | MK-5172 (Grazoprevir) | MK-5172 is a novel NS3/4, a protease inhibitor for chronic HCV infection (Enzyme Ki for genotype1b, 2a, 2b and 3a at ＜0.02, 0.15, 0.02 and 0.7 nM, respectively). |
| M3321 | GSK1292263 | GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. |
| M3435 | Saxagliptin | Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active inhibitor of dipeptidyl peptidase 4 (DPP-4) (Ki = 0.6-1.3 nM). Saxagliptin can be used in type 2 diabetes studies. |
| M3445 | ADX-47273 | ADX47273 is a potent and specific mGlu5 positive allosteric modulator(PAM) with EC50 of 0.17 μM, showing no activity at other mGlu subtypes. |
| M3481 | WAY-100635 Maleate | WAY 100635 is a potent and selective 5-HT1A receptor agonist with pIC50 of 8.87, exhibits >100-fold selectivity against other 5-HT receptor subtypes and major neurotransmitter receptors. |
| M3613 | NP118809 | NP-118809 (39-1B4) is a potent N-type calcium channel blockers (IC50= 0.11 uM) ; good selectivity over L-type calcium channels. |
| M3680 | GS-9451 | GS-9451, a novel hepatitis C virus (HCV) nonstructural 3/4a (NS3/4a) protease inhibitor, is highly active in patients infected with HCV genotype 1 (GT 1). |
| M3957 | Mitiglinide calcium | Mitiglinide (KAD 1229, S 21403), a derivative of benzysuccinic acid, is a potassium channel antagonist developed with Kissei for the study of type 2 diabetes. |
| M3975 | PF-06463922 | Lorlatinib (PF-06463922) is an oral active, selective, brain osmotic and ATP-competitive ROS1/ALK inhibitor. The Ki of Lorlatinib for ROS1, wild-type ALK and ALKL1196M were <0.025 nM, <0.07 nM and 0.7 nM, respectively. Lorlatinib has anticancer activity. |
| M4138 | Deucravacitinib (BMS-986165) | Deucravacitinib (BMS-986165) is a first-in-class, selective, orally bioavailable inhibitor of TYK2 transitions.Deucravacitinib selectively binds the TYK2 pseudokinase (JH2) structural domain with an IC50 of 1.0 nM and a Ki value of 0.02 nM. Deucravacitinib (BMS-986165) blocks receptor-mediated Tyk2 activation by stably regulating the JH2 structural domain. deucravacitinib also inhibits the IL-12/23 and type I IFN pathways. deucravacitinib may be used in psoriasis research. |
| M4433 | Alantolactone | Alantolactone is a selective STAT3 inhibitor, with potent anticancer activity. Alantolactone (helenin, helenine, Eupatal) could induce activin/SMAD3 signaling and disrupt Cripto-1/activin receptor type II A interaction. |
| M4545 | Isorhamnetin-3-O-neohespeidoside | Isorhamnetin-3-o-neohespeidoside is a flavonoid isolated from Pollen typhae. |
| M4852 | LY303511 | LY303511 is a structural analogue of LY294002, which does not inhibit PI3K, increased homotypic GJIC. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
